Clinical Trial Update: Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction [Phase 3]

View source ↗

Summary

Phase 3 trial comparing LCZ696 (sacubitril/valsartan) to valsartan on cognitive function in patients with chronic heart failure with preserved ejection fraction…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• LCZ696 (sacubitril/valsartan) (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Heart Failure (CHF) | Phase 3 | Status: COMPLETED | Results posted: 2024-08-06